NAYA Biosciences, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NAYA research report →
Companywww.nayabiosciences.com
INVO Bioscience is a medical device company providing devices and products for infertility diagnosis. Its flagship product is INVOcell, a reproductive technology that allows fertilization and early embryo development to take place within the woman’s body.
- CEO
- Steven M. Shum
- IPO
- 2020
- Employees
- 30
- HQ
- Sarasota, US
Price Chart
Valuation
- Market Cap
- $1.47M
- P/E
- -0.03
- P/S
- 0.44
- P/B
- 0.20
- EV/EBITDA
- -0.47
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 39.75%
- Op Margin
- -634.43%
- Net Margin
- -632.75%
- ROE
- -261.48%
- ROIC
- -112.75%
Growth & Income
- Revenue
- $6.53M · 116.25%
- Net Income
- $-9,095,838 · -13.21%
- EPS
- $-30.19 · -488.41%
- Op Income
- $-8,125,496
- FCF YoY
- 39.26%
Performance & Tape
- 52W High
- $17.04
- 52W Low
- $1.38
- 50D MA
- $2.64
- 200D MA
- $7.37
- Beta
- 2.04
- Avg Volume
- 1.56M
Get TickerSpark's AI analysis on NAYA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our NAYA Coverage
We haven't published any research on NAYA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NAYA Report →